Stock Analysis on Net

Illumina Inc. (NASDAQ:ILMN)

This company has been moved to the archive! The financial data has not been updated since November 5, 2021.

Analysis of Profitability Ratios 
Quarterly Data

Microsoft Excel

Profitability Ratios (Summary)

Illumina Inc., profitability ratios (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Return on Sales
Gross profit margin 69.30% 68.63% 67.61% 68.01% 69.02% 70.34% 70.36% 69.63% 69.24% 68.84% 69.06% 69.01% 69.44% 68.85% 67.98% 66.35% 65.68% 66.26% 67.53% 69.48%
Operating profit margin -0.75% 17.02% 16.82% 17.91% 22.08% 25.69% 27.28% 27.80% 26.42% 24.88% 25.58% 26.49% 28.25% 27.58% 26.29% 22.02% 20.01% 20.06% 21.35% 24.48%
Net profit margin 21.17% 19.36% 18.14% 20.25% 19.70% 20.68% 26.49% 28.28% 28.13% 27.55% 25.05% 24.78% 21.09% 20.88% 19.31% 26.38% 30.14% 30.07% 30.52% 19.29%
Return on Investment
Return on equity (ROE) 8.55% 14.83% 12.80% 13.98% 13.57% 15.19% 20.32% 21.72% 21.92% 21.65% 21.36% 21.98% 19.53% 19.90% 18.85% 26.41% 27.38% 27.54% 29.01% 21.06%
Return on assets (ROA) 6.01% 8.85% 7.20% 8.65% 8.62% 9.56% 12.97% 13.70% 13.73% 13.45% 11.52% 11.87% 10.12% 11.08% 10.23% 13.81% 15.49% 15.39% 16.10% 10.81%

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).


Over the periods analyzed, the gross profit margin generally exhibits stability with minor fluctuations, ranging between approximately 65.68% and 70.36%. From late 2016 through the end of 2017, the margin slightly declined from around 69.48% to 65.68% but subsequently increased and stabilized near the upper 60% range through late 2021. This suggests a relatively consistent ability to manage production costs relative to revenue over the years.

The operating profit margin demonstrates a more variable trend. Initial data points indicate a margin above 20%, which rises notably to nearly 28.25% by the end of 2018. However, following this peak, the margin declines steadily, dropping to negative territory (-0.75%) by late 2021. This downward trend, particularly the sharp fall in the latest period, could reflect increasing operating expenses, declining operational efficiency, or other cost-related pressures affecting profitability.

Net profit margin shows significant variability throughout the observed periods. It reaches a high of over 30% in mid to late 2016 but then sees fluctuations with declines and recoveries, settling around the range of 18% to 28% over much of the timeline. The margin falls to approximately 18.14% - 21.17% near the end of the series, indicating some challenges in maintaining net profitability despite earlier higher margins.

Return on equity (ROE) follows a similar pattern to net profit margin, with peaks exceeding 29% in mid to late 2016 and considerable variability thereafter. After those early highs, ROE gradually declines, stabilizing near 21% through 2017 and 2018, but then falls further to around 8.55% by late 2021. This decline suggests a decreasing efficiency in generating profits from shareholders' equity over time.

Return on assets (ROA) trends align with the patterns observed in ROE and net profit margin. ROA peaks near 16.1% in mid-2016 and remains relatively consistent through 2017 before gradually lowering to 6.01% by the end of 2021. The reduction in ROA indicates diminished effectiveness in utilizing company assets to produce profits.

In summary, the company maintains a stable gross profit margin, indicating steady core operational management regarding cost of goods sold. However, operating profit margin, net profit margin, ROE, and ROA all exhibit a declining trend over the most recent years, culminating in a negative operating profit margin in late 2021. This combination points to increasing operational and overall profitability challenges, potentially arising from higher operating costs, lower revenue growth, asset utilization inefficiencies, or other financial pressures.


Return on Sales


Return on Investment


Gross Profit Margin

Illumina Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Gross profit 770 802 764 630 526 428 619 662 648 573 584 590 597 575 538 542 482 434 368 419 426 424 397
Revenue 1,108 1,126 1,093 953 794 633 859 952 907 838 846 868 853 830 782 778 714 662 598 619 607 600 572
Profitability Ratio
Gross profit margin1 69.30% 68.63% 67.61% 68.01% 69.02% 70.34% 70.36% 69.63% 69.24% 68.84% 69.06% 69.01% 69.44% 68.85% 67.98% 66.35% 65.68% 66.26% 67.53% 69.48%
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc. 67.72% 65.62% 64.82% 66.41%
Amgen Inc. 74.00% 73.97% 74.37% 74.59%
Bristol-Myers Squibb Co. 76.92% 75.88% 74.42% 72.31%
Danaher Corp. 60.44% 59.24% 57.60% 55.98%
Eli Lilly & Co. 74.85% 74.27% 75.88% 77.66%
Gilead Sciences Inc. 80.23% 79.90% 80.32% 81.23%
Johnson & Johnson 67.51% 67.00% 66.24% 65.58%
Merck & Co. Inc. 67.95% 67.48% 66.99% 67.74%
Pfizer Inc. 65.28% 70.96% 76.46% 79.26%
Regeneron Pharmaceuticals Inc. 86.65% 86.85% 86.84% 86.82%
Thermo Fisher Scientific Inc. 51.05% 51.29% 51.47% 49.67%
Vertex Pharmaceuticals Inc. 87.94% 87.89% 88.06% 88.14%

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
Gross profit margin = 100 × (Gross profitQ3 2021 + Gross profitQ2 2021 + Gross profitQ1 2021 + Gross profitQ4 2020) ÷ (RevenueQ3 2021 + RevenueQ2 2021 + RevenueQ1 2021 + RevenueQ4 2020)
= 100 × (770 + 802 + 764 + 630) ÷ (1,108 + 1,126 + 1,093 + 953) = 69.30%

2 Click competitor name to see calculations.


The analysis of the quarterly financial data indicates several notable trends in gross profit, revenue, and gross profit margin over the reported periods.

Gross Profit
Gross profit exhibits a general upward trajectory from April 2016 through October 2021, increasing from 397 million US dollars to 770 million US dollars. Despite fluctuations, periods of significant growth are observed, such as from late 2016 to the end of 2017, where gross profit rose steadily from 419 million to 542 million US dollars. A temporary decline occurs around mid-2020, with figures dropping to 428 million US dollars, likely reflecting external impacts during that period. Following this dip, gross profit recovers and even surpasses previous highs, reaching a peak of 802 million US dollars in July 2021 before a slight decrease in October 2021.
Revenue
Revenue figures also show a rising trend similar to gross profit, moving from 572 million US dollars in early 2016 to 1,108 million US dollars by the last reported quarter. The revenue growth is relatively consistent, with minor fluctuations corresponding broadly to those seen in gross profit. A notable contraction occurs in mid-2020, with revenues decreasing to 633 million US dollars from 952 million US dollars the previous quarter, mirroring the gross profit decline. Subsequently, revenue picks up strongly, reaching its highest level in October 2021 at 1,126 million US dollars before a slight decline.
Gross Profit Margin
The gross profit margin is relatively stable and consistently strong throughout the periods, predominantly ranging between 65% and 70%. From 2016 to early 2017, the margin shows a slight decrease, stabilizing in the mid to high 60% range thereafter. Notably, gross profit margin peaks around 70.36% in mid-2020, even during a quarter of reduced revenue and gross profit, suggesting maintained operational efficiency or cost control. Margins then slightly normalize but remain close to 69% by the end of the most recent period.

In summary, the data reveals steady growth in both gross profit and revenue over multiple years with a pronounced but temporary downturn during mid-2020, possibly linked to broader economic conditions. Despite this, gross profit margin remains robust and fairly consistent, indicating effective cost management and pricing strategies. The recovery in gross profit and revenue following the dip underscores resilience and a positive long-term growth outlook.


Operating Profit Margin

Illumina Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Income (loss) from operations (545) 187 193 133 162 96 189 268 308 205 204 197 241 227 218 230 181 143 52 143 161 162 121
Revenue 1,108 1,126 1,093 953 794 633 859 952 907 838 846 868 853 830 782 778 714 662 598 619 607 600 572
Profitability Ratio
Operating profit margin1 -0.75% 17.02% 16.82% 17.91% 22.08% 25.69% 27.28% 27.80% 26.42% 24.88% 25.58% 26.49% 28.25% 27.58% 26.29% 22.02% 20.01% 20.06% 21.35% 24.48%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc. 30.09% 28.95% 23.63% 24.81%
Amgen Inc. 30.14% 30.72% 37.23% 37.70%
Bristol-Myers Squibb Co. -15.73% -17.02% -19.19% -21.60%
Danaher Corp. 24.63% 25.04% 22.30% 18.99%
Eli Lilly & Co. 23.17% 21.81% 22.06% 24.69%
Gilead Sciences Inc. 42.79% 37.20% 18.07% 16.72%
Johnson & Johnson 24.69% 25.23% 24.10% 23.60%
Merck & Co. Inc. 14.07% 10.64% 14.02% 16.47%
Pfizer Inc. 24.67% 24.12% 21.20% 19.47%
Regeneron Pharmaceuticals Inc. 55.19% 53.94% 43.37% 42.09%
Thermo Fisher Scientific Inc. 27.04% 28.00% 27.68% 24.19%
Vertex Pharmaceuticals Inc. 37.17% 33.93% 47.14% 46.03%

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
Operating profit margin = 100 × (Income (loss) from operationsQ3 2021 + Income (loss) from operationsQ2 2021 + Income (loss) from operationsQ1 2021 + Income (loss) from operationsQ4 2020) ÷ (RevenueQ3 2021 + RevenueQ2 2021 + RevenueQ1 2021 + RevenueQ4 2020)
= 100 × (-545 + 187 + 193 + 133) ÷ (1,108 + 1,126 + 1,093 + 953) = -0.75%

2 Click competitor name to see calculations.


The operating income and revenue data over the analyzed quarters reveal distinct patterns and fluctuations. Initially, income from operations exhibits moderate volatility with values ranging from 52 million to 308 million US dollars between early 2016 and late 2019. Notably, there is a significant uptick around the third and fourth quarters of 2019, where income peaks at 308 million before declining again.

Revenue demonstrates a generally increasing trend throughout the period from April 2016 to October 2021. Starting at 572 million US dollars, revenue gradually rises almost consistently, reaching a high of 1126 million in the third quarter of 2021. Minor declines or plateau phases occur sporadically but do not substantially detract from the overall upward momentum.

Examining the operating profit margin, available from late 2016 onward, the margin maintains a largely stable level in the 20-28% range for most quarters, indicating consistent operational efficiency relative to revenue. Margins appear to peak around mid-2018, reaching above 28%, before exhibiting a gradual downward trend to approximately 17% by mid-2021. This decrease coincides with a pronounced decline in operating income during the 2020 period, despite revenues rebounding or increasing, suggesting increased operating costs or reduced profitability efficiency in the latter periods.

The most striking anomaly appears in the last quarter of the data in October 2021, where income from operations records a significant loss of 545 million US dollars. This sharp downturn contrasts with relatively high revenue levels (1108 million US dollars) and a near-break-even operating margin at -0.75%. This could indicate either extraordinary expenses, write-downs, or other adverse financial events impacting operational profitability sharply during that quarter.

Overall, the data portray a company with generally growing sales but fluctuating operational profitability. The steady decrease in operating margins in recent years and the substantial loss in the last reported quarter highlight potential challenges in maintaining profitability despite strong revenue performance.


Net Profit Margin

Illumina Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Net income attributable to Illumina stockholders 317 185 147 257 179 47 173 239 234 296 233 210 199 209 208 68 163 128 367 124 129 120 90
Revenue 1,108 1,126 1,093 953 794 633 859 952 907 838 846 868 853 830 782 778 714 662 598 619 607 600 572
Profitability Ratio
Net profit margin1 21.17% 19.36% 18.14% 20.25% 19.70% 20.68% 26.49% 28.28% 28.13% 27.55% 25.05% 24.78% 21.09% 20.88% 19.31% 26.38% 30.14% 30.07% 30.52% 19.29%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc. 13.66% 12.40% 10.28% 10.08%
Amgen Inc. 23.03% 23.80% 29.60% 29.97%
Bristol-Myers Squibb Co. -11.89% -11.44% -14.53% -21.20%
Danaher Corp. 20.97% 21.00% 19.17% 16.36%
Eli Lilly & Co. 21.52% 22.71% 23.91% 25.24%
Gilead Sciences Inc. 27.21% 19.62% 1.19% 0.51%
Johnson & Johnson 19.55% 19.92% 17.95% 17.82%
Merck & Co. Inc. 15.09% 11.83% 15.09% 14.72%
Pfizer Inc. 28.77% 23.86% 24.03% 22.95%
Regeneron Pharmaceuticals Inc. 51.65% 50.11% 43.53% 41.35%
Thermo Fisher Scientific Inc. 21.93% 22.47% 22.08% 19.79%
Vertex Pharmaceuticals Inc. 30.52% 29.80% 43.06% 43.70%

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
Net profit margin = 100 × (Net income attributable to Illumina stockholdersQ3 2021 + Net income attributable to Illumina stockholdersQ2 2021 + Net income attributable to Illumina stockholdersQ1 2021 + Net income attributable to Illumina stockholdersQ4 2020) ÷ (RevenueQ3 2021 + RevenueQ2 2021 + RevenueQ1 2021 + RevenueQ4 2020)
= 100 × (317 + 185 + 147 + 257) ÷ (1,108 + 1,126 + 1,093 + 953) = 21.17%

2 Click competitor name to see calculations.


Revenue Trends
Revenue shows a generally increasing trend from April 2016 through October 2021, starting at $572 million and reaching a peak of $1,126 million in July 2021. There are some fluctuations observed, such as a notable decline to $633 million in June 2020, likely reflecting external factors impacting sales during that period. Following this dip, revenue rebounded strongly in subsequent quarters, returning to above $1 billion by early 2021.
Net Income Attributable to Stockholders
Net income exhibits significant variability across the quarters. Initially rising from $90 million in April 2016 to a high of $367 million in April 2017, it then declines sharply in subsequent quarters, reaching a low of $47 million in June 2020. After this low point, net income recovers, reaching $317 million by October 2021. This pattern suggests volatility in profitability, possibly due to varying operational performance or extraordinary items impacting earnings.
Net Profit Margin
Net profit margin remained relatively strong and stable from December 2016 onward, predominantly staying within the 18% to 30% range. The highest margins occurred between April 2017 and December 2019, peaking over 30% around mid-2017. A dip is observable around mid-2020 concurrent with the decrease in net income and revenue during that period, with margins falling below 20%. Margins gradually improved again toward the end of 2021, indicating a recovery in profitability despite revenue fluctuations.
Insights and Patterns
The data reveals a cyclical nature in profitability and revenue, with a notable downturn around mid-2020 aligning with global challenges during that period. Despite this, the company demonstrated resilience with recovery in both revenue and net income following this downturn. High net profit margins suggest an ability to maintain operational efficiency even in less favorable quarters. The fluctuations in net income relative to revenue changes imply sensitivity to external market or operational factors affecting profitability.

Return on Equity (ROE)

Illumina Inc., ROE calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Net income attributable to Illumina stockholders 317 185 147 257 179 47 173 239 234 296 233 210 199 209 208 68 163 128 367 124 129 120 90
Total Illumina stockholders’ equity 10,593 5,180 4,922 4,694 4,700 4,563 4,635 4,613 4,439 4,332 3,985 3,758 3,503 3,257 3,008 2,749 2,855 2,715 2,551 2,197 2,240 2,056 1,991
Profitability Ratio
ROE1 8.55% 14.83% 12.80% 13.98% 13.57% 15.19% 20.32% 21.72% 21.92% 21.65% 21.36% 21.98% 19.53% 19.90% 18.85% 26.41% 27.38% 27.54% 29.01% 21.06%
Benchmarks
ROE, Competitors2
AbbVie Inc. 55.60% 53.01% 37.63% 35.30%
Amgen Inc. 68.26% 69.67% 75.91% 77.20%
Bristol-Myers Squibb Co. -14.52% -13.80% -16.54% -23.84%
Danaher Corp. 13.54% 13.12% 11.76% 9.17%
Eli Lilly & Co. 76.99% 94.20% 88.31% 109.79%
Gilead Sciences Inc. 34.44% 26.20% 1.59% 0.68%
Johnson & Johnson 25.44% 25.53% 22.96% 23.25%
Merck & Co. Inc. 20.10% 16.73% 26.08% 27.91%
Pfizer Inc. 26.28% 18.86% 16.23% 15.21%
Regeneron Pharmaceuticals Inc. 40.53% 41.02% 33.43% 31.86%
Thermo Fisher Scientific Inc. 22.13% 23.32% 22.60% 18.47%
Vertex Pharmaceuticals Inc. 22.83% 21.66% 30.76% 31.22%

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
ROE = 100 × (Net income attributable to Illumina stockholdersQ3 2021 + Net income attributable to Illumina stockholdersQ2 2021 + Net income attributable to Illumina stockholdersQ1 2021 + Net income attributable to Illumina stockholdersQ4 2020) ÷ Total Illumina stockholders’ equity
= 100 × (317 + 185 + 147 + 257) ÷ 10,593 = 8.55%

2 Click competitor name to see calculations.


The financial data for the given periods reveals several notable trends and fluctuations across the key indicators.

Net Income Attributable to Illumina Stockholders
There is a general pattern of considerable volatility in net income over the reported quarters. Initially, net income ranged between 90 million and 129 million US dollars during 2016. A significant spike was observed in April 2017, where net income dramatically increased to 367 million US dollars, followed by sharp declines and fluctuations in subsequent quarters. The net income was relatively stable between 200 million and 300 million US dollars during 2018 and 2019, although some quarters showed declines. In 2020, a notable decrease occurred, with net income dropping to as low as 47 million US dollars in the second quarter. The most recent quarters in 2021 indicate a recovery and growth, reaching a peak of 317 million US dollars in the last quarter reported.
Total Illumina Stockholders’ Equity
Stockholders’ equity shows a consistent upward trend over the period analyzed. Beginning at approximately 1,991 million US dollars in early 2016, equity steadily increased each quarter, reaching 5,180 million US dollars by October 2021. This progression reflects ongoing capitalization and accumulation of retained earnings or other equity components without any noticeable setbacks or declines.
Return on Equity (ROE)
ROE data is available from late 2016 onward and exhibits a pattern initially indicating strong profitability, with values exceeding 20% and peaking close to 29%. Throughout 2017 and 2018, ROE fluctuated but largely remained above 18%, indicating consistent returns on equity. However, starting in 2019 and continuing into 2020, there is a clear downward trajectory, with ROE decreasing to as low as approximately 8.5% by late 2021. This decline suggests either reduced profitability in relation to equity or growth in equity outpacing net income increments, the latter possibly inferred given the steady rise in equity despite fluctuating net income.

In summary, the company exhibited significant volatility in net income, a consistently increasing equity base, and a declining return on equity trend in the most recent years. The data suggests that while the company has strengthened its equity position, profitability relative to equity has diminished, particularly noticeable after 2019. The recovery in net income during 2021 is positive; however, the reduced ROE indicates that translating earnings into returns for shareholders has become less efficient compared to previous years.


Return on Assets (ROA)

Illumina Inc., ROA calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Net income attributable to Illumina stockholders 317 185 147 257 179 47 173 239 234 296 233 210 199 209 208 68 163 128 367 124 129 120 90
Total assets 15,063 8,675 8,755 7,585 7,404 7,248 7,261 7,316 7,089 6,973 7,390 6,959 6,759 5,851 5,542 5,257 5,046 4,858 4,598 4,281 4,228 3,985 3,794
Profitability Ratio
ROA1 6.01% 8.85% 7.20% 8.65% 8.62% 9.56% 12.97% 13.70% 13.73% 13.45% 11.52% 11.87% 10.12% 11.08% 10.23% 13.81% 15.49% 15.39% 16.10% 10.81%
Benchmarks
ROA, Competitors2
AbbVie Inc. 5.06% 4.50% 3.43% 3.07%
Amgen Inc. 8.63% 9.61% 11.33% 11.54%
Bristol-Myers Squibb Co. -4.87% -4.58% -5.53% -7.61%
Danaher Corp. 7.13% 7.19% 6.30% 4.79%
Eli Lilly & Co. 12.39% 12.70% 13.01% 13.28%
Gilead Sciences Inc. 11.02% 7.59% 0.45% 0.18%
Johnson & Johnson 9.98% 10.07% 8.76% 8.41%
Merck & Co. Inc. 7.70% 6.14% 7.73% 7.72%
Pfizer Inc. 11.10% 7.78% 7.01% 6.23%
Regeneron Pharmaceuticals Inc. 29.55% 28.88% 22.53% 20.47%
Thermo Fisher Scientific Inc. 11.64% 12.70% 12.02% 9.23%
Vertex Pharmaceuticals Inc. 17.25% 16.30% 22.80% 23.07%

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
ROA = 100 × (Net income attributable to Illumina stockholdersQ3 2021 + Net income attributable to Illumina stockholdersQ2 2021 + Net income attributable to Illumina stockholdersQ1 2021 + Net income attributable to Illumina stockholdersQ4 2020) ÷ Total assets
= 100 × (317 + 185 + 147 + 257) ÷ 15,063 = 6.01%

2 Click competitor name to see calculations.


The net income attributable to stockholders exhibits considerable fluctuations throughout the observed periods. Initially, net income demonstrates a positive trend, increasing from 90 million US dollars to a peak of 367 million by April 2017. This peak is followed by a decline, with values dropping notably to 68 million by December 2017. Subsequently, net income generally recovers, stabilizing mostly between 199 million and 317 million in the later periods. However, variability remains evident, with some quarters such as June 2020 showing a significant dip to 47 million and the latest quarter reaching 317 million, indicating inconsistent earnings performance over time.

Total assets show a steady upward trend across the entire timeframe. Starting from 3,794 million US dollars, the asset base expands to 15,063 million by the last recorded period. This steady growth underscores ongoing asset accumulation or investment, with a particular acceleration evident in the final quarter, where assets increase sharply from 8,675 million to 15,063 million. This substantial asset growth in the latest period may indicate significant acquisitions, investments, or revaluations.

The return on assets (ROA) data, though incomplete in earlier periods, reveals an overall downward trajectory after an initial peak. From a high point near 16.1% observed around mid-2016, ROA gradually decreases to approximately 6.01% by the latest reported quarter. The decline suggests that despite growing total assets, the company’s efficiency in generating net income relative to its asset base has weakened. This reduction in asset profitability could reflect pressure on profit margins, increased asset base not yet yielding proportional income, or other operational challenges.

In summary, the company's financial performance shows mixed signals: net income experiences volatility but generally remains positive, total assets consistently grow with a marked surge recently, and returns on assets decline over time, suggesting reduced efficiency in asset utilization during the latter part of the period under review.